Helus Pharma (Cybin Inc.) HELP
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · helus.com
Clinical-stage pharmaceutical company (legal name Cybin Inc., rebranded Helus Pharma in January 2026, when its US listing moved from NYSE American CYBN to Nasdaq HELP) developing proprietary novel serotonergic agonists for depression, anxiety and other mental health conditions. Its lead program HLP003, an FDA Breakthrough Therapy-designated deuterated psilocin analogue, is in Phase 3 for adjunctive treatment of major depressive disorder; also listed on Cboe Canada under HELP.